Dr Neal Shore, Assoc. Prof. Neeraj Agarwal and Prof. Steven Joniau provide their thoughts and views on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials.


An update on recent cutting-edge trials: Treatments now available for newly diagnosed mHSPC patients

Dr Neal Shore, Assoc. Prof. Neeraj Agarwal, and Prof. Steven Joniau provide their thoughts on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials. These slides and video cover recent trials including CHAARTED, STAMPEDE, and LATITUDE. We are given an update on combination trials and how these might improve patient care while moving away from monotherapy.

Emerging treatment options

Dr Shore gives a comprehensive introduction, outlining the need for improved treatment options in prostate cancer. Data from the CHAARTED trial is discussed, in which androgen ablation therapy is used with or without docetaxel chemotherapy for treatment of patients with metastatic prostate cancer. Drug efficacy of systemic therapy in advancing or metastatic prostate cancer is evaluated in the STAMPEDE trial. The LATITUDE trial examines androgen deprivation therapy with abiraterone acetate plus prednisone in newly diagnosed high-risk metastatic hormone-naïve prostate cancer patients. Dr Shore discusses survival benefits and hazard ratios (HRs) and addresses clinical questions regarding treatment protocols, how to monitor subpopulations of patients needing tailored care, and what decisions need to be made following castration-resistance.

The North American perspective in treating prostate cancer

Prof. Agarwal gives us the North American perspective and addresses what treatment options to offer patients in a backdrop of limited data comparing docetaxel chemotherapy to abiraterone acetate. The pros and cons of treatment options are covered as well as considerations in patient and practitioner choice. Addressed are future directions including the role of biomarkers in treatment choice.

The European perspective in treating prostate cancer

Finally, Prof. Joniau provides insight into the European perspective. He covers the European Association of Urology treatment guidelines, and treatment selection factors to be considered when deciding on whether to combine ADT with abiraterone or docetaxel. Highlighted are patients with oligo-metastatic disease, and how ongoing studies aim to address current gaps in knowledge when treating this patient group. This video with accompanying slides provides practical guidance to oncologists and urologists, and we hope you find it a useful resource for improving your clinical practice.

Steven Joniau graduated in Urology in 2002 at the Catholic University of Leuven. In 2003, he was appointed full-time staff member at the Dept. of Urology, University Hospitals Leuven after a 1-year fellowship at the University Hospital of Wales, Cardiff, UK. In July 2012, he obtained his PhD in Medical Sciences entitled ‘High-risk localized prostate cancer: the role of surgery and the development of clinical outcome prediction models’. In 2013, he was appointed Assistant Professor at the Catholic University of Leuven. His principal field of interest is the management of urological cancers. He is heavily involved in uro- oncological surgery and the multidisciplinary approach of pelvic cancers. He also leads numerous research projects at the University Hospitals Leuven, which focus on lymph node staging in prostate cancer, surgical management and biomarker development of high-risk prostate cancer, the natural history of premalignant lesions of the prostate, chemoprevention of prostate and bladder cancer, minimally invasive treatment of renal cell cancer and prostate cancer, etc. Steven Joniau is scientific secretary of the BVU (Belgische Vereniging voor Urologie), he is past- chairman of the Renal Cell Carcinoma Group of the Young Academic Urologists Working Party of the EAU, he is member of the EAU Guideline Panel on Prostate Cancer and the SIOG Prostate Cancer Guideline Panel. He is also a member of several international scientific societies: EAU, SIU (Société Internationale d’Urologie), SIOG (International Society of Geriatric Oncology) and EORTC GUCG (European Organisation for Research and Treatment of Cancer, Genito-Urinary Cancers Group). He is appointed Associate Editor of ‘The Journal of OncoPathology’. He is Editorial Advisory Board member of ‘The European Journal of Surgical oncology’, Editorial Board member of ‘The Open Prostate Cancer Journal’, ‘Archivo Italiano di Urologia e Andrologia’, ‘The Central European Journal of Urology’ and International Scientific Board member of ‘Archivos Españoles de Urología’. Steven Joniau has received several international awards, of which the First prize of the Urological Challenge Session, received at the 2010 European Urology Forum in Davos, Switzerland, the Crystal Matula Award 2011, received at the 2011 EAU annual congress in Vienna, Austria and the biannual Orion International Oncology Award 2011, received at the 2011 EAU annual congress in Vienna, Austria are the most prestigious. In the last 10 years, he has published >170 papers in peer-reviewed journals in the field of uro- oncology and minimally invasive surgery. He received the Prize for the Best Paper published on Clinical Research in the Urological Literature at the EAU annual congress in Stockholm. He authored several book chapters, he has been invited Faculty in over 85 international congresses and is a faculty member of the ESU (European School of Urology).
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer

An expert overview of the EMERALD subgroup analysis

Experts
Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)

Managing patients with nccRCC: guidelines, recommendations, and best practice

Experts
Prof. Laurence Albiges
Endorsed by
Urobel VZW | ASBL
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
micro-learning Micro learning
Oncology 
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Risk factors, diagnostic tools and treatment options for different patient groups

Experts
Prof. Efrat Dotan, Prof. Shubham Pant
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Ipsen USA.
conference-update Conference update
Oncology 
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update

Exploring emerging treatment strategies presented at SABCS 2024

Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2024

This programme has been sponsored by PMV Pharma.